Table 2 Main characteristics of the selected studies
Trial | Author | MF | Tumor stage | Chemotherapy (wks) | Anti-HER2 therapy | HER2+ patients | HR+/− patients (%) | Outcomes |
|---|---|---|---|---|---|---|---|---|
ALTTO | Alvaro Moreno-Aspitia 2021 [20] Martine Piccart-Gebhart 2016 [26] | 6.9 years | I–III | *D1: chemotherapy×(12–18) *D2: A×(9–12) + Taxane×12 *D2B: (Doc + Carb)×18 | T+L T→L L T | 2093 2091 2100 2097 | 4805 (57)/3576 (43) | a, c, f, j, k |
CHER-Lob | Valentina Guarneri 2021 [21] Valentina Guarneri 2015 [27] Valentina Guarneri 2012 [28] | 9 years | II–IIIA | #wP×12 + FEC×12 | T+L L T | 46 39 36 | 28 (61)/18 (39) 24 (62)/15 (38) 21 (58)/15 (42) | a, d, f, i, j, k |
TRIO-US B07 | Sara A. Hurvitz 2020 [22] | NR | I–III | #Doc×18 + Carb×18 | T+L L T | 58 36 34 | 34 (59)/24 (41) 18 (50)/18 (50) 20 (59)/14 (41) | d, j, k |
CALGB 40601 | Aranzazu Fernandez-Martinez 2020 [29] Lisa A. Carey 2016 [30] | 83 months | II–III | #wP×16 *AC×(8-12) | T+L L T | 118 67 120 | 70 (59)/48 (41) 39 (58)/28 (42) 70 (58)/50 (42) | a, d, e, f, j, k |
NeoALTTO | Jens Huober 2019 [31] Evandro de Azambuja 2014 [32] C. Criscitiello 2013 [33] José Baselga 2012 [34] | 6.7 years | I–III | #wP×12 *FEC×9 | T+L L T | 152 154 149 | 77 (51)/75 (49) 80 (52)/74 (48) 75 (50)/74 (50) | a, c, d, e, g, i, j, k |
GeparQuinto | Michael Untch 2018 [35] Michael Untch 2012 [36] | 55 months | I–III | #EC×12 + Doc×12 | L T | 308 307 | 171 (56)/137 (44) 170 (55)/137 (45) | a, c, d, e, f, g, h, i, j, k |
WJOG6110B/ELTOP | Toshimi Takano 2018 [37] | 44.6 months | MBC | C until progression or intolerable toxicity | L T | 43 43 | 27 (63)/16 (37) 27 (63)/16 (37) | a, b, g, h, j, k |
CEREBEL | Xavier Pivot 2015 [38] | NR | MBC | C×NR | L T | 271 269 | NR NR | a, b, g, h, k |
NCIC CTG MA.31 | Karen A. Gelmon 2015 [39] | 21.5 months | MBC | Taxane×24 | L T | 270 267 | NR NR | a, b, g, h, j, k |
EORTC 10054 | H. Bonnefoi 2014 [40] | NR | IIA–IIIC | #Doc×9 → FEC×9 | T+L L T | 52 23 53 | 25 (48)/26 (50) 15 (65)/8 (35) 27 (51)/26 (49) | d, e, g, h, i, j, k |
GEICAM/2006-14 | E Alba 2014 [41] | NR | I–III | #EC×12 → Doc×12 | L T | 51 48 | NR NR | d, e, g, i, j, k |
NSABP B-41 | André Robidoux 2013 [42] | 1.9 years | IIA–IIIA | #AC×12 → Doc×16 | T+L L T | 174 174 181 | 108 (62)/66 (38) 101 (58)/73 (42) 122 (67)/59 (33) | d, e, g, i, j, k |
LPT109096 | Frankie Ann Holmes 2013 [43] | NR | II–III | #FEC×12 + wP×12 | T+L L T | 33 34 33 | 20 (61)/13 (39) 14 (41)/20 (59) 15 (45)/18 (55) | d, g, k |